IceCure Medical (ICCM) announced it is in continued discussions with the U.S. FDA regarding its De Novo marketing authorization request for ProSense in early-stage low risk breast cancer with endocrine therapy. The company now expects the FDA’s marketing authorization decision to be reached after the first quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s ProSense® Cryoablation Showcased at St. Gallen Breast Cancer Conference
- IceCure Medical Expands Global Patent Portfolio with New Cryogenic Pump Approval in China
- IceCure Medical receives Notice of Allowance from CNIPA
- IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study
- IceCure Medical Seeks Israeli Approval for Advanced Cryoablation System